Moreover, the discovery of SELENBP1 as a candidate tumor suppressor emphasizes its importance in guiding both clinical risk categorization and the design of personalized treatment strategies for individuals classified as high-risk LUAD cases. This evidence concerns the gene SELENBP1 and neoplasm.